triptorelin

Product name

Triptorelin

Chemical name

PGLU-HIS-TRP-SER-TYR-D-TRP-LEU-ARG-PRO-GLY-NH2;PYROGLU-HIS-TRP-SER-TYR-D-TRP-LEU-ARG-PRO-GLY NH2;PYR-HIS-TRP-SER-TYR-D-TRP-LEU-ARG-PRO-GLY-NH2;PYR-HIS-TRP-SER-TYR-D-TRP-LEU-ARG-PRO-GLY-NH2 PAMOATE SALT;TRIPTORELIN PAMOATE;TRIPTORELIN ACETATE;TRIPTORELIN AMIDE;TRIPTORELIN, [DTRP6]-LH-RH, AMIDE

CAS NO.

57773-63-4

Formula

C64H82N18O13

Color

white powder

Application

a gonadotropin-releasing hormone agonist(GnRH agonist) used as the acetate or pamoate salts. By causing constant stimulation of the pituitary, it decreases pituitary secretion of gonadotropins luteinizing hormone (LH) andfollicle stimulating hormone (FSH). Like other GnRH agonists, triptorelin may be used in the treatment of hormone-responsive cancers such as prostate cancer or breast cancer, precocious puberty, estrogen-dependent conditions (such as endometriosisor uterine fibroids), and in assisted reproduction. It is also used as therapy for gender identity disorder. Triptorelin is marketed under the brand names Decapeptyl (Ipsen) andDiphereline and Gonapeptyl (Ferring Pharmaceuticals). In the United States, it is sold by Watson Pharmaceuticals asTrelstar. In Iran Triptorelin is marketed under the brand name Variopeptyl (Varian Darou Pajooh).

During the treatment of prostate cancer it does cause a surge of testosterone (an initial uplevel of testosterone levels), known as a flare effect. In men a reduction of serum testosterone levels into the range normally seen after surgical castration occurs approximately two to four weeks after initiation of therapy. In contrast, gonadotropin-releasing hormone antagonists do not cause a surge, but a sudden reduction of testosterone levels.

2, Dose

Usual Adult Dose for Prostate Cancer

Due to different release characteristics, the dosage strengths are not additive and must be selected based upon the desired dosing schedule.

3.75 mg intramuscularly (IM) every 4 weeks
or
11.25 mg IM every 12 weeks
or
22.5 mg IM every 24 weeks